v3.26.3
Segment Information - Reportable Segment Information (Detail) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Net sales $ 1,942 $ 1,869 $ 5,802 $ 5,838
Cost of sales (1,117) (1,070) (3,295) (3,363)
Research & development expenses (170) (162) (494) (487)
Selling & administrative expenses (387) (348) (1,158) (1,147)
Adjusted Operating EBITDA   384 1,244 1,227
Depreciation & Amortization (156) (151) (462) (439)
Interest Expense (46) (48) (136) (180)
Other expense, net (14) (13) (47) (52)
Restructuring Charges (5) (14) (15) (49)
Impairment (23) 0 (23) (34)
(Gains) losses on business disposals 2 0 1 (111)
Loss on held for sale classification (236)   (263)  
Divestiture And Integration Costs (10) (11) (25) (88)
Strategic initiative costs (9) (10) (27) (24)
Regulatory costs (34) (7) (115) (71)
Gain (loss) on extinguishment of debt 0 0 0 488
Tax realignment costs     (2) (5)
Other gains (losses) (6)   (4) (6)
(Loss) Income from continuing operations before taxes (134) 130 126 656
Segment capital expenditures 109 81 342 288
Taste        
Segment Reporting [Line Items]        
Restructuring Charges (2) (9) (7) (19)
Health & Biosciences        
Segment Reporting [Line Items]        
Restructuring Charges (2) (4) (7) (15)
Scent        
Segment Reporting [Line Items]        
Restructuring Charges (1) (1) (1) (15)
Operating Segments        
Segment Reporting [Line Items]        
Net sales 1,942 1,869 5,802 5,838
Adjusted Operating EBITDA from Continuing Operations 403 384 1,244 1,227
Operating Segments | Taste        
Segment Reporting [Line Items]        
Net sales 687 658 2,055 1,962
Cost of sales (419) (399) (1,227) (1,190)
Research & development expenses (46) (41) (139) (131)
Selling & administrative expenses (116) (112) (344) (321)
Depreciation expense add-back (a) 22 17 59 49
Adjusted Operating EBITDA from Continuing Operations 128 123 404 369
Segment capital expenditures 34 21 101 76
Operating Segments | Health & Biosciences        
Segment Reporting [Line Items]        
Net sales 566 559 1,742 1,638
Cost of sales (305) (299) (927) (875)
Research & development expenses (56) (57) (167) (163)
Selling & administrative expenses (105) (101) (324) (294)
Depreciation expense add-back (a) 36 32 102 90
Adjusted Operating EBITDA from Continuing Operations 136 134 426 396
Operating Segments | Scent        
Segment Reporting [Line Items]        
Net sales 689 652 2,005 1,869
Cost of sales (392) (372) (1,141) (1,051)
Research & development expenses (67) (64) (187) (184)
Selling & administrative expenses (112) (107) (321) (298)
Depreciation expense add-back (a) (21) (18) (58) (50)
Adjusted Operating EBITDA from Continuing Operations 139 127 414 386
Segment capital expenditures 23 21 92 74
Operating Segments | Pharma Solutions        
Segment Reporting [Line Items]        
Net sales       369
Cost of sales       (248)
Research & development expenses       (8)
Selling & administrative expenses       (42)
Depreciation expense add-back (a)       (5)
Adjusted Operating EBITDA from Continuing Operations       76
Segment capital expenditures     0 38
Operating Segments | Health And Biosciences        
Segment Reporting [Line Items]        
Segment capital expenditures $ 52 $ 39 $ 149 $ 100